Metraipolis › archive › dc_524fcb043bb7

Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit — Europe PMC PMID:41301008

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41301008
DOI
10.3390/cancers17223641
License (as archived)
solo-consultazione
Archived
2026-11-08T14:15:04.959Z
SHA-256 of the archived text
976c780741b7a8f73a54049513e8ebb8ee8a69c07fbbc8b66d7bfed55ac08b88
Stable URL of this page
https://metraipolis.com/documento/dc_524fcb043bb7

How to cite

Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit — Europe PMC PMID:41301008 — Europe PMC (en), https://europepmc.org/article/MED/41301008 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_524fcb043bb7 (Metraipolis archive dc_524fcb043bb7, sha256 976c780741b7a8f73a54049513e8ebb8ee8a69c07fbbc8b66d7bfed55ac08b88)
BibTeX
@misc{dc524fcb043bb7,
  title = {Optimal Timing of Treatment Initiation in Non-Metastatic Castration-Resistant Prostate Cancer Based on PSA Level and Doubling Time for Prognostic Benefit — Europe PMC PMID:41301008},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41301008},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_524fcb043bb7; sha256 976c780741b7a8f73a54049513e8ebb8ee8a69c07fbbc8b66d7bfed55ac08b88},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41301008. Agents can read the archived copy with the MCP tool read_document.